Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients.
Zhong L, Gan L, Wang B, Wu T, Yao F, Gong W, Peng H, Deng Z, Xiao G, Liu X, Na J, Xia D, Yu X, Zhang Z, Xiang B, Huo Y, Yan D, Dong Z, Fang F, Ma Y, Jin G, Su D, Liu X, Li Q, Liao H, Tang C, He J, Tang Z, Zhang S, Qiu B, Yang Z, Yang L, Chen Z, Zeng M, Feng R, Jiao J, Liao Y, Wang T, Wu L, Mi Z, Liu Z, Shi S, Zhang K, Shi W, Zhao Y.
Zhong L, et al.
Cell. 2025 Feb 20;188(4):1119-1136.e23. doi: 10.1016/j.cell.2024.12.010. Epub 2025 Jan 17.
Cell. 2025.
PMID: 39826543
Free article.